Table 2.
Clinical characteristics
| All values are n (%) unless stated otherwise | Patients (N=146) |
| Use contact lenses | 20 (13.7) |
| Screen exposure, hours | |
| 0–<1 | 10 (6.8) |
| 1–2 | 16 (11.0) |
| 3–4 | 48 (32.9) |
| 5–6 | 36 (24.7) |
| 7–15 | 36 (24.7) |
| Current type of treatment | |
| Preserved | 33 (22.6) |
| Non-preserved (eg, hydroxypropyl cellulose ophthalmic insert) | 52 (35.6) |
| Prescription eye drops (eg, lifitegrast, cyclosporine) | 73 (50.0) |
| Specialty drugs | 11 (7.5) |
| Compounded ointments | 12 (8.2) |
| Gel (eg, loteprednol etabonate) | 21 (21.2) |
| Other | 39 (26.7) |
| None | 8 (5.5) |
| Sjögren’s syndrome | |
| No | 122 (83.6) |
| Yes | 12 (8.2) |
| I do not know | 11 (7.5) |
| Unknownb | 1 (0.7) |
| Patient-reported severity of DED | |
| Mild | 17 (11.6) |
| Moderate | 28 (19.2) |
| Severe | 101 (69.2) |
| DED duration, years | |
| 1–5 | 90 (61.6) |
| 6–10 | 28 (26.0) |
| 10–35 | 18 (12.3) |
*'Unknown’ indicates that no answer was provided.
†Including hypertension, antidiabetic and analgesic medications.
‡For example, Sjögren’s syndrome, rheumatoid arthritis, lupus.
§For example, mood, depression, anxiety.
¶Including laser-assisted in situ keratomileusis or photorefractive keratectomy.
DED, dry eye disease; GvHD, graft versus host disease; HRT, hormone replacement therapy; HSCT, haematopoietic stem cell transplantation.